Opioid therapy offers the promise of reducing the burden of chronic pain in not just individual patients, but among the broad population of patients with chronic pain. Randomized trials have demonstrated that opioid therapy for up to 12-16 weeks is superior to placebo, but have not addressed longer-term use. In the United States, opioid sales have quadrupled during 2000-2010, with parallel increases in opioid accidental overdose deaths and substance abuse admissions. Clinical use of long-term opioid therapy is characterized by a pattern of adverse selection, where high-risk patients are prescribed high-risk opioid regimens. This adverse selection may link these trends in use, abuse, and overdose. Long-term opioid therapy appears to be associated with iatrogenic harm to the patients who receive the prescriptions and to the general population. The United States has, in effect, conducted an experiment of population-wide treatment of chronic pain with long-term opioid therapy. The population-wide benefits have been hard to demonstrate, but the harms are now well demonstrated. Ó
Introduction
''Among the remedies which it has pleased Almighty God to give to man to relieve his sufferings, none is so universal and so efficacious as opium. '' -Thomas Sydenham (1692) In the past few decades, we have witnessed the success of the ethical argument for pain treatment. This success was first accomplished by the hospice and palliative care community with the argument that dying in pain is ethically unacceptable. Arguments about turning dying patients into addicts were definitively and universally rejected. Even if pain treatment hastens death, this treatment is now considered ethically appropriate if the patient or authorized proxies choose to receive it [31] . In subsequent years, the ethical mandate for pain relief as basic care has been extended from end of life to all cancer pain. In 1985 and in 1996, the World Health Organization issued guidelines on cancer pain relief [77] . Moderate to severe pain is common in cancer patients, and unfortunately, many patients still do not get adequate relief [12] .
This ethical mandate for pain treatment has recently been extended to chronic noncancer pain [11] . We have previously made the argument that chronic noncancer pain produces suffering and disability at least equal to that of cancer pain, but with higher prevalence and longer duration (Sullivan and Ferrell, 2005) [64]. In 2010, the International Association for the Study of Pain issued the Declaration of Montreal, which argued for ''access to pain management without discrimination . . . on the basis of age, sex, gender, medical diagnosis, race or ethnicity, religion, culture, marital, civil or socioeconomic status, sexual orientation, and political or other opinion'' [39] . Prohibition of discrimination on the basis of ''medical diagnosis'' is meant to prohibit favoring cancer pain treatment over noncancer pain treatment. In 2011, the Institute of Medicine in the United States issued a report on Relieving Pain in America [38] . In this report, prevalent pain is considered to be undertreated pain. This suggests that all pain justifies treatment, regardless of origin.
The above arguments for pain management as a fundamental human right have addressed pain treatment broadly. Indeed, some of them have specifically mentioned that this does not imply a universal right to receive opioid therapy. There has been a separate and more specific ethical argument made for opioid treatment. In 1986, Portenoy and Foley published a review of 38 cases of chronic noncancer pain successfully treated with opioids [55] . In this article, they argue that ''opioid maintenance therapy can be a safe, salutary and more humane alternative . . . in those patients with intractable non-malignant pain and no history of drug abuse'' [55] . In more recent years, these authors have acknowledged problems associated with widespread prescribing of opioids for noncancer pain, but have reiterated their support for the practice [54] . For example, they have resisted opioid-dosing guidelines that mandate specialist review if a patient exceeds a specific dose with-
